Simvastatin is a Small Molecule owned by Merck & Co, and is involved in 51 clinical trials, of which 50 were completed, and 1 is ongoing.
Simvastatin is a prodrug and is hydrolyzed to its active Beta-hydroxyacid form, simvastatin acid, after administration. Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol. In addition, simvastatin reduces VLDL and TG and increases HDL-C.
The revenue for Simvastatin is expected to reach a total of $433m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Simvastatin NPV Report.
Simvastatin is currently owned by Merck & Co. Organon is the other company associated in development or marketing of Simvastatin.
Simvastatin (Zocor, Sinvacor, Lipex, Lodales, Zocor Heart-Pro, Zocord, Sivastin, Simovil) is a lipid-lowering agent which is synthetically derived from a fermentation product of Aspergillus terreus. It is formulated as tablets, coated tablets and film coated tablets for oral route of administration. It is used to treat high cholesterol, hypercholesteremia, heterozygous and homozygous familial hypercholesteremia, hyperlipidemia, hypertriglyceredemia, mixed dyslipidemia, dysbetalipoproteinemia . It is also used in patients at high risk of coronary events like the risk reduction of coronary heart disease deaths, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures.
Organon is a healthcare company. The company discovers and develops biosimilars and medicines. It provides medicines and solutions for various conditions including respiratory, cardiovascular, dermatology, non-opioid pain, women’s health and others. The company’s products include mometasone furoate inhalation powder, follitropin beta injection, alendronate sodium, acetate injection, chorionic gonadotropin and others. It conducts patient assistance and Organon access program, which provide free medicines to individuals. Organon markets its products through a network of distribution channels in domestic and overseas markets. It works in collaboration with pharmaceutical and biopharmaceutical companies to commercialize its products. Organon is headquartered in Jersey City, New Jersey, the US.
The company reported revenues of (US Dollars) US$6,304 million for the fiscal year ended December 2021 (FY2021), a decrease of 3.5% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 42.1% in FY2020. In FY2021, the company recorded a net margin of 21.4%, compared to a net margin of 33.1% in FY2020. The company reported revenues of US$1,537 million for the third quarter ended September 2022, a decrease of 3% over the previous quarter.
Quick View – Simvastatin
|Highest Development Stage|